ArticleCancer management and research2018

Matching-adjusted indirect treatment comparison of ribociclib and palbociclib in HR+, HER2- advanced breast cancer.

Gabriel Tremblay et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.